Blakolmer K, Vesely M, Kummer J A, Jurecka W, Mannhalter C, Chott A
Department of Clinical Pathology, General Hospital Vienna, University of Vienna, Austria.
Mod Pathol. 2000 Jul;13(7):766-72. doi: 10.1038/modpathol.3880133.
The monoclonal antibodies L26 (CD20) and CD79a are very useful reagents for the immunohistochemical assessment of B-cell lineage in lymphoproliferative disorders. Although very few CD20-positive peripheral T-cell lymphomas (PTL) have been reported, comprehensive analyses of CD79a reactivity in extranodal PTL and NK/T-cell lymphomas have not been performed previously. This study investigated CD79a (clone JCB117) and CD20 reactivity in 94 extranodal non-B-cell lymphomas (enteropathy-type intestinal T-cell lymphoma [n = 52], nasal NK/T-cell lymphoma [n = 11], and primary cutaneous PTL [n = 31]) and in 17 cases of nodal PTL, unspecified. In four cases (enteropathy-type intestinal T-cell lymphoma [n = 3] and nasal NK/T-cell lymphoma [n = 1]), the majority of tumor cells stained for CD79a (all CD20 negative) and one cutaneous PTL, unspecified, was CD20 positive (CD79a negative). Extensive immunophenotyping and polymerase chain reaction-based molecular analyses revealed that all five B-cell marker-positive extranodal lymphomas had a cytotoxic phenotype and did indeed represent monoclonal peripheral T-cell proliferations. To minimize the risk of misinterpretation of lymphoma cell lineage, especially in cases of extranodal, lymphoproliferative disease, we suggest the use of both CD79a and CD20 in combination with a panel of antibodies reactive to T cells, such as betaF1 and CD5, and to T cells and NK cells, such as CD3, CD2, CD56, and TIA-1.
单克隆抗体L26（CD20）和CD79a是用于免疫组织化学评估淋巴增殖性疾病中B细胞谱系的非常有用的试剂。尽管报道的CD20阳性外周T细胞淋巴瘤（PTL）极少，但此前尚未对结外PTL和NK/T细胞淋巴瘤中的CD79a反应性进行全面分析。本研究调查了94例结外非B细胞淋巴瘤（肠病型肠T细胞淋巴瘤[n = 52]、鼻NK/T细胞淋巴瘤[n = 11]和原发性皮肤PTL[n = 31]）以及17例未明确类型的结内PTL中CD79a（克隆JCB117）和CD20的反应性。在4例病例（肠病型肠T细胞淋巴瘤[n = 3]和鼻NK/T细胞淋巴瘤[n = 1]）中，大多数肿瘤细胞CD79a染色阳性（所有CD20阴性），1例未明确类型的皮肤PTL CD20阳性（CD79a阴性）。广泛的免疫表型分析和基于聚合酶链反应的分子分析显示，所有5例B细胞标志物阳性的结外淋巴瘤均具有细胞毒性表型，确实代表单克隆外周T细胞增殖。为了将淋巴瘤细胞谱系误判的风险降至最低，尤其是在结外淋巴增殖性疾病的病例中，我们建议联合使用CD79a和CD20，并结合一组对T细胞有反应的抗体，如βF1和CD5，以及对T细胞和NK细胞有反应的抗体，如CD3、CD2、CD56和TIA-1。
